Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
TENUATE is an oral small-molecule tablet approved in 1975 as a legacy NDA product by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting characterization of its therapeutic role.
Product faces near-term loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting commercial team and transition-focused roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
Synbiotic to Attenuate Resorption of the Skeleton
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Worked on TENUATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TENUATE represents a legacy product nearing loss of exclusivity with zero linked job openings, signaling limited career growth opportunity. Roles supporting this product focus on generic transition, cost management, and operational efficiency rather than innovation or expansion.